-
New Analyses from Pivotal Phase III Trials of Oral Ozanimod in Relapsing Multiple Sclerosis To Be Presented at the 2018 American Academy of Neurology Annual Meeting
biospace
April 25, 2018
Celgene Corporation today announced additional phase III data analyses evaluating the efficacy and safety of ozanimod, a novel, oral, selective sphingosine 1-phosphate 1 and 5 receptor modulator, versus interferon beta-1a
-
Novartis Published Multiple Sclerosis Trial Data With Plans to File for FDA Approval
biospace
March 26, 2018
Novartis released full results from its Phase III EXPAND trial of siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS), which it published in the journal The Lancet.
-
Game-changer" stem cell transplant shows strength in multiple sclerosis
pharmafile
March 20, 2018
CNS’ treatments are notoriously risky, especially those that are still at an early stage; however, Lundbeck has decided to take a calculated risk on Prexton Therapeutics and its sole candidate for Parkinson’s.
-
Potential new approach to the treatment of multiple sclerosis
worldpharmanews
March 13, 2018
A prospective new method of treating patients with multiple sclerosis has been proposed by researchers of the Mainz University Medical Center working in cooperation with researchers of the University of Montreal.
-
Merck KGaA, Darmstadt, Germany, Announces Positive Phase IIB Results for Evobrutinib in Relapsing Mu
biospace
March 08, 2018
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced positive results from its Phase IIb study of evobrutinib in relapsing multiple sclerosis (MS)
-
Blood test may help predict disease activity in MS
europeanpharmaceuticalreview
December 01, 2017
A blood test to monitor a nerve protein in the blood of people with multiple sclerosis may help predict whether disease activity is flaring up…
-
Allergy drug improves function in patients with chronic injury from multiple sclerosis
worldpharmanews
October 12, 2017
In a remarkably rapid translation of laboratory research findings into a treatment with the potential to benefit patients, UC San Francisco scientists have successfully completed a Phase II clinical trial
-
Merck KGaA to take on Biogen, Novartis with long-sought EMA nod for MS pill
fiercepharma
August 28, 2017
Merck KGaA hopes the unique dosing schedule for its new MS pill will make the drug stand out from rivals.
-
Digital-minded Novartis taps Apple's ResearchKit for smartphone MS study
fiercepharma
August 24, 2017
Novartis has been quick to embrace sensor technology, launching a Qualcomm smart inhaler collaboration last year.
-
Novartis launches multiple sclerosis study using data collected from smartphones
firstwordpharma
August 23, 2017
Novartis announced the launch of the elevateMS trial to collect data via smartphones, which will provide researchers with new ways to look at how the disease progresses and effectiveness of treatment.